Skip to main content
OpenTrials
Completed

NCT Number: NCT01914302

The Characterization of Blood Volumes of Commercially Available Lancing Devices

Characterize expressed blood volume ≥1μL across representative, commercially available lancing device systems using finger sticks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Facet Technologies

Kennesaw, Georgia, 30144, United States

About this study

Primary Objective:

  • Characterize expressed blood volume ≥1μL across representative, commercially available lancing device systems using finger sticks.

Secondary Objectives: the following characterizations will be performed in the data analysis within each device and across each device:

  • Correlation of Subject pain response to blood volume collected;
  • Proportion of Subjects that produce sufficient blood to fill a 1µl test strip;
  • Proportion of Subjects that generate ≥1µl blood volume;
  • Proportion of Subjects who generate multiple- times the blood volume needed to fill a 1µl test strip
  • Proportion of Subjects who generate multiple- times ≥1µl of blood volume
  • Proportion of Subjects that produce on average (≥1µl) of blood volume on 1st attempt
  • Proportion of Subjects that produce on average (≥1µl) of blood volume on their first and second lancing attempt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be diagnosed with type 1 or type 2 diabetes for one (1) or more year(s).
  • Must be currently self-monitoring blood glucose levels for at least 6 months.
  • Must self-test at least 2 times daily.
  • Must be between the ages of 18 and 75 to participate.
  • Subjects must be able to perform all tasks required in this protocol.
  • Subjects must be willing to complete all study procedures.
  • Subjects must be able to speak, read and understand English and understand the Informed Consent document.

Exclusion criteria

  • Subjects with neuropathy or any other nerve damage in the hand or fingers (this will be discovered through the monofilament test)
  • Subjects who are taking prescription anti-coagulants or more than one full aspirin per day during the past week or have clotting problems that may prolong bleeding (persons taking Plavix or a daily low dose aspirin will not be excluded but this will be recorded).
  • Subjects taking pain relievers within 24 hours.
  • Subjects with hemophilia or any other bleeding disorder.
  • Subjects with infection with a blood borne pathogen (e.g., HIV, hepatitis).
  • Subjects having a condition such as a cognitive disorder, which in the opinion of the Investigator would put the person at risk or seriously compromise the integrity of the study (PI will sign Case Report Form if Subject is excluded).
  • Subjects working for Facet, LifeScan Inc., or a competitive company.
  • Subjects with missing digits.
  • Subjects who are pregnant or nursing.
  • Subjects on chemotherapy.

Treatment and study plan

Delica Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Flash Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Easy Touch Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Glucoject Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Microlet Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Multiclix Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Fastclix Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Reli-On Lancing Device

Device

Characterize Blood Volume and Pain under normal use circumstances

Primary outcomes

  1. Blood Volumes measured in microliters

    Time frame: between 1 and 10 days after first visit

    Study subject lances assigned finger and acquires blood drop; at that time the study facilitator gathers blood in pipette and measures on scale

Secondary outcomes

  1. Pain rating measure on a 0-20 Gracely Scale

    Time frame: between 1 and 10 days after first visit

    Subjects were asked to rate pain on Gracely scale after each lancing even on the finger

Sponsors and collaborators

Lead sponsor

Facet Technologies

Other

Collaborators

  • LifeScan

Registry information

Official study title

Lancing Device Blood Volume Study

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Aug 2, 2013
Registry last updated
Aug 2, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.